Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Shire Licenses Parion's Dry Eye Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News

Shire Licenses Parion’s Dry Eye Drug

Gains exclusive rights to develop and commercialize P-321, an investigational epithelial sodium channel (ENaC) inhibitor

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Shire plc and Parion Sciences, Inc. have entered an agreement granting Shire exclusive rights to develop and commercialize P-321, an investigational epithelial sodium channel (ENaC) inhibitor in Phase II development for the treatment of dry eye disease.   

P-321 is being developed to address tear volume deficiency and promote ocular surface healing and is believed to address dry eye disease by inhibiting ENaC, which is thought to block the absorption of tears. Current prescription treatments target the effects of ocular inflammation.  

Shire will make an initial $20 million upfront payment with an additional $20 million based on development milestones. Parion will be entitled to receive additional milestone payments, with a total consideration of as much as $535 million. Parion has the option to co-fund through additional stages of development in exchange for royalties. Parion also has the option to co-fund commercialization activities.

“Ophthalmics is a continued focus for Shire, and the program for P-321 will benefit from our development and commercial infrastructure and expertise,” said Flemming Ornskov, chief executive officer, Shire. “This is an opportunity to apply our knowledge and experience from ophthalmics and dry eye disease for further innovation in this space. If approved, P-321 would expand our eye care portfolio.”

“Advancing P-321 with Shire, an emerging global leader in ophthalmics, offers the expertise and resources to move this promising potential therapy for dry eye sufferers forward,” said Paul Boucher, president and chief executive officer of Parion. “This collaborative license agreement enables us the opportunity to contribute and participate in P-321’s success, while continuing our drive to progress Parion’s pipeline of novel therapies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics